

Hybridoma Anti-Monkeypox Virus Viral Chemokine Inhibitor (vCCI), Clone 3D1

Catalog No. NR-10509

For research use only. Not for human use.

Contributor:

Dr. Scott W. Wong, Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, USA

Manufacturer:

BEI Resources

Product Description:

The murine hybridoma cell line, NR-10509, was generated by the fusion of NS-1 myeloma cells with splenocytes from BALB/c mice immunized with a bacterially-expressed recombinant form of the monkeypox virus viral chemokine inhibitor (vCCI; viral CC chemokine binding protein).

Material Provided:

Each vial contains approximately 1 mL of cell culture suspension frozen in cell growth medium (90%) and DMSO (10%) cryopreservative. Sufficient cells are provided to initiate at least one new culture. The cell count, expressed as cells per vial, is shown on individual certificates of analysis for each lot.

Packaging/Storage:

This product was packaged aseptically, in screw-capped plastic cryovials. It should be stored at -100°C or colder, preferably in the vapor phase of a liquid nitrogen freezer. Storage at -70°C will result in loss of viability. To ensure the highest level of viability, the vial should be thawed and the culture initiated as soon as possible upon receipt. Any warming of the product during shipping and transfer must be avoided, as this will adversely affect the viability of the product after thawing. For transfer between freezers and shipping, the cells may be placed on dry ice for brief periods, although use of a portable liquid nitrogen carrier is preferred. Please read the following recommendations prior to reconstituting this material.

Safety Precautions:

When handling frozen vials it is highly recommended that protective gloves, lab coat and full face mask be worn. Even brief exposure to the ultra-cold temperature can cause tissue damage from frostbite. Also, some vials may slowly fill with liquid nitrogen if they have been immersed during cryogenic storage. When thawing, the liquid nitrogen may rapidly expand as it changes to gas, breaking the vial or cap with explosive force, sending debris flying with enough velocity to cause injury. Store and use in areas with adequate ventilation.

Thawing and Growth:

Prior to thawing the hybridoma cells, prepare growth medium (GM) for use. Hybridoma cells are grown in Opti-MEM®

(Invitrogen™ 51985) modified to contain 10% irradiated fetal bovine serum (FBS; Lonza 14-471F), 2 mM L-glutamine (Invitrogen™ 25030-081) and 1 mM sodium pyruvate (Invitrogen™ 11360-070). This GM is formulated for use with a 5% CO₂ in air atmosphere.

Rapidly thaw the vial of hybridoma cells in a 37°C water bath with gentle agitation. To reduce the risk of contamination, keep the cap and O-ring of the vial out of the water and repeatedly check the cap for tightness during thawing. Remove from the water bath immediately when thawed. Dry the vial with a sterile wiper, decontaminate using a wiper soaked with 70% isopropyl alcohol, and let the vial air dry. Aseptically open the vial, remove the vial contents and add to 4 mL of pre-warmed (37°C for 15 to 30 minutes) GM in a centrifuge tube. Centrifuge the cell suspension at 125 to 200 × g for 8 to 10 minutes at 18°C to 25°C. Discard the supernatant and resuspend the cell pellet at a density of approximately 250,000 viable cells per mL in pre-warmed GM. Transfer the cell suspension into a 25 cm² tissue culture flask. Incubate the new culture at 37°C and 5% CO₂. Subculture at a density of 10⁵ to 10⁶ viable cells per mL approximately every 48 to 96 hours. Do not allow the culture to go more than 4 days without fresh GM.

Citation:

Acknowledgment for publications should read “The following reagent was provided by the NIH Biodefense Proteomics Research Centers, NIAID, for distribution through BEI Resources, NIAID, NIH: Hybridoma Anti-Monkeypox Virus Viral Chemokine Inhibitor (vCCI), Clone 3D1, NR-10509.”

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmb15/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. [Resource Center for Biodefense Proteomics Research, NR-10509.](#)
2. Jones, J. M., et al. "Monkeypox Virus Viral Chemokine Inhibitor (MPV vCCI), a Potent Inhibitor of Rhesus Macrophage Inflammatory Protein-1." *Cytokine* 43 (2008): 220-228. PubMed: 18639466.

ATCC® is a trademark of the American Type Culture Collection.

